Betabloqueadores e hipertension arterial

59

description

rol de los betabloqueadores en hipertension arterial

Transcript of Betabloqueadores e hipertension arterial

Page 1: Betabloqueadores e hipertension arterial
Page 2: Betabloqueadores e hipertension arterial
Page 3: Betabloqueadores e hipertension arterial
Page 4: Betabloqueadores e hipertension arterial
Page 5: Betabloqueadores e hipertension arterial
Page 6: Betabloqueadores e hipertension arterial
Page 7: Betabloqueadores e hipertension arterial
Page 8: Betabloqueadores e hipertension arterial
Page 9: Betabloqueadores e hipertension arterial

Lancet. 2005;366:1545-53.

Page 10: Betabloqueadores e hipertension arterial
Page 11: Betabloqueadores e hipertension arterial
Page 12: Betabloqueadores e hipertension arterial
Page 13: Betabloqueadores e hipertension arterial
Page 14: Betabloqueadores e hipertension arterial
Page 15: Betabloqueadores e hipertension arterial
Page 16: Betabloqueadores e hipertension arterial
Page 17: Betabloqueadores e hipertension arterial
Page 18: Betabloqueadores e hipertension arterial
Page 19: Betabloqueadores e hipertension arterial
Page 20: Betabloqueadores e hipertension arterial
Page 21: Betabloqueadores e hipertension arterial
Page 22: Betabloqueadores e hipertension arterial
Page 23: Betabloqueadores e hipertension arterial
Page 24: Betabloqueadores e hipertension arterial
Page 25: Betabloqueadores e hipertension arterial
Page 26: Betabloqueadores e hipertension arterial

Hypertension

Volume 59(4):893-898

March 14, 2012

Page 27: Betabloqueadores e hipertension arterial
Page 28: Betabloqueadores e hipertension arterial

Risk/Benefit Assessment of β-Blockers

and Diuretics Precludes Their Use for

First-Line Therapy in Hypertension

by Franz H. Messerli, Sripal Bangalore, and Stevo Julius

Circulation

Volume 117(20):2706-2715

May 20, 2008

Copyright © American Heart Association

Page 29: Betabloqueadores e hipertension arterial

Figure 6. Risk of new-onset diabetes

mellitus with antihypertensive treatment.

Messerli F et al. Circulation 2008;117:2706-2715

Copyright © American Heart Association

Page 30: Betabloqueadores e hipertension arterial
Page 31: Betabloqueadores e hipertension arterial
Page 32: Betabloqueadores e hipertension arterial

USADA guide to prohibited classes of substances and prohibited methods of doping. Retrieved October 2001, from http://www.usantidoping.org/prohibited_sub/guide.asp.

Page 33: Betabloqueadores e hipertension arterial
Page 34: Betabloqueadores e hipertension arterial
Page 35: Betabloqueadores e hipertension arterial
Page 36: Betabloqueadores e hipertension arterial
Page 37: Betabloqueadores e hipertension arterial
Page 38: Betabloqueadores e hipertension arterial
Page 39: Betabloqueadores e hipertension arterial

ARCH INTERN MED/VOL 170 (NO. 10), MAY 24, 2010

Page 40: Betabloqueadores e hipertension arterial
Page 41: Betabloqueadores e hipertension arterial
Page 42: Betabloqueadores e hipertension arterial
Page 43: Betabloqueadores e hipertension arterial
Page 44: Betabloqueadores e hipertension arterial
Page 45: Betabloqueadores e hipertension arterial
Page 46: Betabloqueadores e hipertension arterial
Page 47: Betabloqueadores e hipertension arterial
Page 48: Betabloqueadores e hipertension arterial
Page 49: Betabloqueadores e hipertension arterial
Page 50: Betabloqueadores e hipertension arterial
Page 51: Betabloqueadores e hipertension arterial
Page 52: Betabloqueadores e hipertension arterial
Page 53: Betabloqueadores e hipertension arterial
Page 54: Betabloqueadores e hipertension arterial
Page 55: Betabloqueadores e hipertension arterial
Page 56: Betabloqueadores e hipertension arterial

Ankle-brachial index in the 2 treatment groups at baseline

and after the 48 week treatment period.

Espinola-Klein C et al. Hypertension 2011;58:148-154

Copyright © American Heart Association

Page 57: Betabloqueadores e hipertension arterial
Page 58: Betabloqueadores e hipertension arterial

2DA GENERACION

3A GENERACION

Page 59: Betabloqueadores e hipertension arterial